How Lucrative Is the Opportunity In the U.S. for Hematology Diagnostic Equipment Manufacturers : Check New Report

According to a new study published by Fact.MR, a market research and competitive intelligence provider, the demand for Americas hematology diagnostics was valued at US$ 264.3 Mn in 2020, and is predicted to expand at a CAGR of around 5% over the forecast period (2021–2031).

Click Here to Get Complete Synopsis of this Report https://www.factmr.com/report/americas-hematology-diagnostics-market

Factors boosting demand for hematology diagnostics include rising incidence of blood-related diseases such as anemia and blood cancer. Hematological tests help in evaluating various conditions involving blood and its components. But these can be also performed to determine various life-threatening diseases at different stages. Blood tests can give an exact assessment of body conditions and result in early treatment.

Advancements in technology have led to the development of simple and painless blood testing systems. Moreover, development prospects of hematology diagnostics are expected to be influenced by rising investments in research & development activities of blood-related diseases. Rising healthcare expenditure and focus are expected to contribute significantly to the growth of the market over the forecast period.

“Growing prevalence of blood-related diseases and rising demand for point of care testing are factors expected to drive market growth over the coming years,” says an analyst of Fact.MR.

To remain ‘ahead’ of your competitors, request for a sample – https://www.factmr.com/connectus/sample?flag=S&rep_id=6513

Key Takeaways from Market Study

Blood typing kits are expected to contribute more than 31% revenue share in the market by 2031.

Under modality, demand for lab-based testing is expected to increase at a CAGR of 5% through the forecast period.

Diagnostic laboratories dominate the market among all distribution channels, and are expect to reach a valuation of US$ 172 Mn by 2031.

The U.S. holds the highest share in the global market due to rising concerns about health and increasing blood related diseases, and is expected to progress at a CAGR of 4% through 2031.

Speak to Research Analyst https://www.factmr.com/connectus/sample?flag=AE&rep_id=6513

Categorization by Americas Hematology Diagnostics Industry Research

By Kit

Hematology Anemia and Iron Test Kits
Hematology Folic Acid Testing Kits
Hematology Sickle Cell Screening Kits
Hematology PT/INR Testing Kits
Hematology D-dimer Testing Kits
Hematology Blood Typing Kits
Hematology Leukemia Testing Kits
Hematology Sepsis Testing Kits
Hematology Antibiotic Resistance Panels
Hematology Bacterial & Fungal Panels

By Modality

Point of Care
Lab-based testing

Distribution Channel

Hematology Diagnostics at Hospitals
Hematology Diagnostics at Diagnostic Laboratories
Hematology Diagnostics at Cancer Research Institutes
Hematology Diagnostics through Retail Pharmacies
Hematology Diagnostics through Drug Stores

Full Access of this Report Is Available At https://www.factmr.com/checkout/6513

Increasing Adoption of Point of Care Services Likely to Propel Market Growth

Point of care tests are gaining popularity because of many factors such as convenience, early diagnosis, and cost effectiveness.

Due to early detection of diseases and the ongoing COVID-19 pandemic, people are opting for point of care diagnosis. It will also reduce the chances of spread of infectious diseases.

Competition Outlook

BioMedomics, Inc.
Biomerieux SA
Abbott Laboratories
BTNX Inc.
i-SENS, Inc.
Danaher
ELDON BIOLOGICALS A/S
F. Hoffmann-La Roche Ltd.

Looking for more information?

The research study on the Americas hematology diagnostics market by Fact.MR incorporates an unbiased assessment of key demand-driving factors and trends, which have shaped the landscape over 2016 – 2020, and includes a detailed assessment of key parameters that are anticipated to exert influence during 2021 – 2031.

Market statistics have been presented based on kit (anemia and iron test kits, folic acid testing kits, sickle cell screening kits, PT/INR testing kits, d-dimer testing kits, blood typing kits, leukemia testing kits, sepsis testing kits, antibiotic resistance panels, and bacterial & fungal panels), modality (point of care and lab-based testing), and distribution channel (hospitals, diagnostic laboratories, cancer research institutes, online sale channels, and drug stores), across North America and Latin America.

For More Insights https://www.prnewswire.com/news-releases/biotechnology-rd-key-for-laboratory-centrifuges-potential-factmr-301252858.html

Key Questions Answered in Report

Which countries will continue to remain the most profitable markets for hematology diagnostics over the coming years?

How will changing trends impact the market?

How has the COVID-19 crisis impacted market growth?

How can market players capture the low-hanging opportunities in developed regions?

What are the strategies of stakeholders to shape their position in this landscape?

What are the restraining factors that investors need to be aware of and might tackle while investing in the market?

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email : sales@factmr.com
Website : https://www.factmr.com

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

This release was published on openPR.